Login to Your Account



EFFICACY, TOO, IN CELGENE PACT

Going up? Bluebird BCMA phase I with CAR T in MM: low tox means dose rising

By Randy Osborne
Staff Writer

Thursday, December 1, 2016

With efficacy data thus far sans toxicity, "our dose escalation continues," Bluebird Bio Inc.'s chief medical officer, David Davidson, told BioWorld Today as onlookers cheered early success with the anti-BCMA chimeric antigen receptor (CAR) T-cell candidate BB2121 for relapsed/refractory multiple myeloma (MM), in development with Celgene Corp.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription